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Introduction {#sec1}
============

From the few studies describing the aetiology of acute lower respiratory tract infections (LRTIs) in primary care patients, we know that most LRTIs in the general community are caused by viral pathogens, in particular rhinovirus, influenza virus, coronavirus (CoV), respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus (PiV) \[[@bib1],[@bib2]\]. The illness course of LRTIs in adults presenting in this setting -- a relatively healthy, working population -- is mostly self-limiting and complications are rare \[[@bib3]\]. However, with an average of 3.5 days of sick leave per year, LRTIs cause a substantial socio-economic burden \[[@bib3],[@bib4]\]. In adults, influenza virus, bacteria and viral--bacterial coinfections are assumed to cause the most severe illnesses, with most systemic symptoms, longest illness durations, and most complications \[[@bib5], [@bib6], [@bib7]\]. However, evidence on associations between aetiology and severity are mainly derived from hospital care settings with vulnerable patient populations \[[@bib8], [@bib9], [@bib10]\]. In this setting, a focus on pathogens with the highest complication rates is obvious. Quite often, however, this focus is also applied in the general community, with public health interventions such as the annual influenza vaccinations targeted at the most vulnerable people with the aim of reducing the risk of complications and death \[[@bib11]\]. Although data on the impact of respiratory viruses in the primary care setting are limited due to restricted microbial testing and absence of a standardized, validated outcome measure to evaluate illness severity \[[@bib12]\], there are studies suggesting that the burden of disease from infections due to respiratory viruses other than influenza -- i.e. rhinovirus, coronavirus and RSV -- may be greater overall \[[@bib13]\]. In this study, we aimed to explore the associations between respiratory viral pathogens, including viral load, and illness course in the adult primary care community, thereby opening up possibilities to base the public health focus on the impact of respiratory viruses in primary care, rather than on extrapolated data from hospital settings. This study was conducted in a large European cohort consisting of prospectively enrolled adult patients with acute cough and/or a clinical suspicion for LRTI.

Methods {#sec2}
=======

Design and study population {#sec2.1}
---------------------------

This prospective study in primary care is part of the GRACE study (Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe). Participants were recruited between November 2007 and April 2010 by general practitioners (GPs) from 16 primary care networks in 11 European countries ([Supplementary Fig. S1](#appsec1){ref-type="sec"}). Patients aged ≥18 years presenting with acute cough (duration of ≤28 days) and/or suspected LRTI, were asked to participate in this study, i.e. to fill out study materials and provide written informed consent \[[@bib14]\]. Exclusion criteria were pregnancy, breast-feeding, any serious immunocompromised condition and antibiotic use in the previous month \[[@bib14]\]. About one-third of these patients agreed to being randomized to either the intervention (amoxicillin) or placebo arm of the original randomized controlled trial \[[@bib14]\]. Remaining patients were not randomly assigned but were included in the observational part of the study \[[@bib1]\]. In the current study, both trial and observational patients were analysed together, but patients without polymerase chain reaction (PCR) and/or serology results on viral aetiology (all due to practical reasons) were excluded. Ethical approval was obtained for all participating networks.

Clinical measurements {#sec2.2}
---------------------

For the collection of clinical data on the day of presentation (baseline), standardized case report forms (CRFs) were used. GPs completed the CRF on the following 12 symptoms rated by the patients using a four-point Likert-scale (1 = no problem, 2 = mild, 3 = moderate, 4 = severe): cough, sputum production, shortness of breath, wheeze, blocked or runny nose, fever, chest pain, muscle aching, headache, disturbed sleep, feeling generally unwell, and interference with normal daily activities. Additionally, the symptoms confusion/disorientation and diarrhoea were rated. Following initial presentation, patients were asked to fill out a symptom diary at home on a daily basis until they had no more symptoms or until the end of follow-up (day 28). Patients were asked to rate the same 12 symptoms by using a seven-point Likert-scale (0 = normal, 1 = very little problem, 2 = slight problem, 3 = moderately bad, 4 = bad, 5 = very bad, 6 = as bad as it could be). This diary was internally reliable, valid, and sensitive to change for acute LRTI \[[@bib15]\].

Microbiological measurements {#sec2.3}
----------------------------

At baseline, two nasopharyngeal flocked swabs were taken by trained staff within 24 h after recruitment and before any antimicrobial treatment had started. Swabs were placed in universal transport medium immediately, frozen locally, and transported on dry ice to the central laboratory (University of Antwerp). Real-time in-house PCR (RT-PCR) testing was performed either as four multiplex RT-PCRs (combining INF-A, INF--B, and RSV; PIV1-4; HRV, hMPV, and the EAV internal control; and finally the human CoV: 229E, OC43, NL63, and HKU1), or as monoplex (all other viruses) \[[@bib16]\]. RNA/DNA extractions and amplification methods were described previously \[[@bib1],[@bib16]\]. Based on the results from our study comparing the prevalence of viral pathogens between symptomatic and asymptomatic matched controls \[[@bib1]\], we evaluated rhinoviruses, influenza viruses, coronaviruses, RSV, hMPV and PiV. Because (pan-)adenovirus (1.3% vs 1.1%, p = 0.33), bocavirus (0.6% vs 0.8%, p = 0.43) and WU/KI polyomaviruses (2.2% vs. 2.5%, p = 0.02) were not detected more frequently in symptomatic patients than in controls, they were not considered pathogenic respiratory viruses and therefore excluded from our analyses \[[@bib1]\]. A cycle threshold (Ct) value -- an inverse, logarithmic, quantitative measurement of viral load -- below 45 was chosen as cut-off for a positive result. We adjusted our analyses for bacterial infections, which were defined as having at least one of the following pathogens detected in a sputum or nasopharyngeal sample: *Streptococcus* species, Gram-negative species, or *Aspergillus* (fungus). Commensals and *Candida* species were considered contaminants for which analyses were not adjusted. Microbiologists who determined the results were blinded to clinical information.

Outcome parameters {#sec2.4}
------------------

We focused on two main outcome parameters: symptom severity at presentation and illness duration. Symptom severity was measured as the mean CRF score for all 12 symptoms (scored 1--4) at baseline \[[@bib14],[@bib17], [@bib18], [@bib19]\]. Illness duration was defined as the duration until absence of any symptoms rated moderately bad or severe (score 3 or above) in the symptom diary following initial presentation \[[@bib14],[@bib17], [@bib18], [@bib19]\]. Additionally, the severity of all individual symptoms was analysed, dichotomizing symptom severity at no/mild/moderate vs severe.

Statistical analysis {#sec2.5}
--------------------

Baseline characteristics were reported as *n* (%), means (standard deviation (SD)) or medians (interquartile range (IQR)) as appropriate. Symptom severity at baseline was analysed with linear regression models and expressed as differences in mean symptom severity with a 95% confidence interval (CI). In an additional step, we analysed the presence of individual symptoms with logistic regression, expressed as odds ratios (ORs). Duration until absence of symptoms rated moderately bad or severe were analysed with Cox proportional hazard models. For the latter analysis, patients were censored at the end of follow-up or if fewer than 10 symptoms were filled out in the symptom diary. If patients already met the event criteria at baseline *(n* = 104), we defined their time to event as 1 day. Results were expressed as hazard ratios (HRs).

For all analyses, we adjusted for the potential confounders defined beforehand (please see Supplementary Material). Statistical analyses were performed using SPSS v.25.0 for Windows and the 'survival' and 'survminer' packages in R v.4. Details of the statistical analysis are described in the Supplementary Material.

Results {#sec3}
=======

Study population {#sec3.1}
----------------

We included 2957 adult patients ([Fig. 1](#fig1){ref-type="fig"} ). Demographics and clinical symptoms at presentation are presented in [Table 1](#tbl1){ref-type="table"} . Patients had a median age of 50 years (IQR 36--63), 1195 (40.4%) were male and 1603 (54.2%) were a former or current smoker. The overall mean symptom score at presentation was 2.09 (95% CI 2.07--2.11). Respiratory viruses (1411) were detected in 1354 patient samples ([Fig. 2](#fig2){ref-type="fig"} ). The proportion of influenza virus positive patients was lower among patients who received the annual influenza vaccination during the preceding fall/winter (38/707, 5.4%) than among non-vaccinated patients (259/2250, 11.5%) (p \<0.001). Follow-up data were available for 2393 patients (80.9%). Baseline disease characteristics did not differ between patients who did (*n* = 2393) or did not (*n* = 564) fill out a symptom diary. Of all 2393 patients included in the symptom duration analysis, 2186 (91.3%) documented resolution of symptoms rated moderately bad or severe before the end of follow-up, with a median duration of 6.00 days (IQR 4.00--11.00 days). At presentation, only two patients were prescribed antiviral medication (oseltamivir).Fig. 1Flow-chart patient exclusion as compared with the total number of patients included in the GRACE cohort \[[@bib1]\]. CRF, case report form; PCR, polymerase chain reaction.Fig. 1Table 1Baseline characteristics included patients (*n* = 2957)Table 1DemographicsPatients (*n* = 2957)[a](#tbl1fna){ref-type="table-fn"}Age (years)50 (36-63)Gender (male)1195 (40.4%)Caucasian ethnicity2862 (96.8%)Comorbidities[b](#tbl1fnb){ref-type="table-fn"} COPD176 (6.0%) Asthma307 (10.4%) Other lung disease62 (2.1%) Heart failure57 (1.9%) Ischemic heart disease159 (5.4%) Other hearth disease111 (3.8%) Diabetes190 (6.4%)Smoking past or current1603 (54.2%)Disease related characteristics at presentationSevere cough983 (33.2%)Sputum production309 (10.4%)Shortness of breath215 (7.3%)Wheeze115 (3.9%)Blocked or runny nose355 (12.0%)Fever122 (4.1%)Chest pain155 (5.2%)Muscle aching163 (5.5%)Headache226 (7.6%)Disturbed sleep542 (18.3%)Feeling generally unwell349 (11.8%)Interference with normal daily activities344 (11.6%)Confusion/disorientation6 (0.2%)Diarrhoea16 (0.5%)One or more abnormalities at lung auscultation1165 (39.4%)Breaths (per min)16 (15-18)Heart rate (beats per min)76 (70-83)Systolic blood pressure (mmHg)127 (117-140)Diastolic blood pressure (mmHg)80 (70-85)Oral temperature (°C)36.7 (36.4-37)Medication prescribed for illness[c](#tbl1fnc){ref-type="table-fn"}2086 (70.5%)[^1][^2][^3][^4]Fig. 2Detected viral pathogens in included patients (*n* = 2957) and availability of follow-up data. CoV, coronavirus; hMPV, human metapneumovirus; IV, influenza virus; PiV, Parainfluenza virus; RV, rhinovirus; RSV, respiratory syncytial virus; Undet, influenza virus type undetermined. ∗ The following combinations of viral pathogens were found: CoV + RV (*n =* 10), IV + RV (*n =* 8), CoV + hMPV (*n =* 5), CoV + RSV (*n =* 4), RV + RSV (*n =* 4), IV + RSV (*n =* 3), CoV + IV (*n =* 2), hMPV + RV (*n =* 2), IV + PiV (*n =* 1), CoV + PiV (*n =* 1), RV + PiV (*n =* 1), RSV + PiV (*n =* 1). ∗∗ The following combinations of viral pathogens were found: CoV + RV (*n =* 5), IV + RV (*n =* 3), CoV + IV (*n =* 3), CoV + RSV (*n =* 1), RV + RSV (*n =* 1), IV + RSV (*n =* 1), RV + PiV (*n =* 1).Fig. 2

Association between respiratory viruses and symptom severity {#sec3.2}
------------------------------------------------------------

We evaluated the severity of symptoms at presentation for patients with CoV, hMPV, influenza virus, PiV, rhinovirus and RSV, as compared with patients without these viruses, with adjustment for confounders, bacteria and co-viruses. Influenza virus, hMPV, RSV, CoV and rhinovirus were significantly associated with, respectively, 0.25 (95% CI 0.19--0.31), 0.16 (95% CI 0.07--0.26), 0.12 (95% CI 0.04--0.21), 0.09 (95% CI 0.02--0.16) and 0.07 (95% CI 0.02--0.12) points higher symptom scores at presentation as compared with patients without detected virus ([Table 2](#tbl2){ref-type="table"} ). Among patients in whom a virus was detected, a 10 cycles lower Ct value -- i.e. a higher viral load -- measured at presentation, was associated with a 0.11 (95% CI 0.06--0.16) point higher mean symptom severity as compared with patients without detected virus. After stratification for viral aetiology, we only observed an association between viral load and symptom severity for rhinovirus (increase of 0.12 per 10 cycles reduction in Ct value, 95% CI 0.04--0.20) and for RSV (increase of 0.16 per 10 cycles reduction in Ct value, 95% CI 0.01--0.30). When looking at differences in the severity of individual symptoms of these viruses ([Fig. 3](#fig3){ref-type="fig"} ), influenza virus was independently associated with severe fever (OR 6.3, 95% CI 4.0--9.8), headache (OR 3.1, 95% CI 2.2--4.5), chest pain (OR 2.0, 95% CI 1.3--3.2), muscle pain (OR 2.5, 95% CI 1.6--3.9), disturbed sleep (OR 1.4, 95% CI 1.1--1.9), being generally unwell (OR 2.5, 95% CI 1.8--3.5), and interference with daily activities (OR 2.5, 95% CI 1.8--3.5). RSV was associated with severe headache (OR 2.0, 95% CI 1.2--3.5), disturbed sleep (OR 1.7, 95% CI 1.1--2.5) and a runny nose (OR 2.9, 95% CI 1.9--4.4). hMPV was associated with severe dyspnoea (OR 2.0, 95% CI 1.0--3.7) and headache (OR 2.0, 95% CI 1.1--3.7). Rhinovirus was associated with severe wheeze (OR 1.6, 95% CI 1.0--2.6), a runny nose (OR 1.6, 95% CI 1.2--2.1) and negatively associated with severe cough (OR 0.8, 95% CI 0.6--0.9). CoV was associated with a severe runny nose (OR 2.0, 95% CI 1.4--3.0) and negatively associated with severe chest pain (OR 0.3, 95% CI 0.1--0.9).Table 2Symptom severity[a](#tbl2fna){ref-type="table-fn"} at presentation in patients consulting in primary care with a detected virus or no detected virus (*n* = 2957)Table 2Mean (SD) symptom score at presentationUnadjusted difference between groups (95% CI)Adjusted difference between groups (95% CI)[b](#tbl2fnb){ref-type="table-fn"}No virus(es) (*n* = 1603)2.02 (0.49)(Ref)(Ref)≥1 virus(es) (*n* = 1354)2.18 (0.52)0.17 (0.13--0.20)0.13 (0.10--0.17)No virus(es) (*n* = 1603)2.02 (0.49)(Ref)(Ref)1 virus (*n* = 1297)2.18 (0.51)0.16 (0.13--0.20)0.13 (0.09--0.16)2 viruses (*n* = 57)2.27 (0.54)0.13 (0.06--0.19)0.22 (0.09--0.35)CoV (*n* = 205)[c](#tbl2fnc){ref-type="table-fn"}2.15 (0.48)0.10 (0.03--0.18)0.09 (0.02--0.16)[d](#tbl2fnd){ref-type="table-fn"}hMPV (*n* = 121)[c](#tbl2fnc){ref-type="table-fn"}2.18 (0.52)0.16 (0.06--0.25)0.16 (0.07--0.26)[d](#tbl2fnd){ref-type="table-fn"}Influenza virus (*n* = 297)[c](#tbl2fnc){ref-type="table-fn"}2.32 (0.55)0.30 (0.23--0.36)0.25 (0.19--0.31)[d](#tbl2fnd){ref-type="table-fn"}PiV (*n* = 73)[c](#tbl2fnc){ref-type="table-fn"}2.13 (0.51)0.10 (-0.01 to 0.22)0.07 (-0.04 to 0.19)[d](#tbl2fnd){ref-type="table-fn"}Rhinovirus (*n* = 572)[c](#tbl2fnc){ref-type="table-fn"}2.15 (0.50)0.12 (0.07--0.16)0.07 (0.02--0.12)[d](#tbl2fnd){ref-type="table-fn"}RSV (*n* = 143)[c](#tbl2fnc){ref-type="table-fn"}2.17 (0.53)0.14 (0.05--0.22)0.12 (0.04--0.21)[d](#tbl2fnd){ref-type="table-fn"}[^5][^6][^7][^8][^9]Fig. 3Forest plots showing odds ratios (ORs) with 95% confidence intervals (CIs) on the log scale for coronavirus (CoV), human metapneumovirus (hMPV), influenza virus, parainfluenza virus (PiV), rhinovirus and respiratory syncytial virus (RSV) for a severe burden of individual symptoms at presentation (highest on four-point Likert scale). The reference category is no virus isolated. ORs are derived from logistic regression models (one model per symptom) with adjustment for bacterial and viral coinfections, age, gender, pulmonary comorbidities (asthma, chronic obstructive pulmonary disease and other lung diseases), hearth failure, current smoking, influenza vaccination during the preceding fall or winter and duration of symptoms before presentation. ∗ For fever and chest pain the scale on the x-axis was altered for visual purposes.Fig. 3

Association between respiratory viruses and illness duration {#sec3.3}
------------------------------------------------------------

After adjustment for bacterial coinfections, baseline symptom severity and other potential confounders, patients with detected viral pathogen(s) had no significantly different HR (0.93, 95% CI 0.86--1.02) for resolution of moderately bad or severe symptoms compared with patients in which no virus was detected ([Table 3](#tbl3){ref-type="table"} ). We also assessed the duration until resolution of moderately bad or severe symptoms for the six individual viruses as compared with patients without a detected virus ([Fig. 4](#fig4){ref-type="fig"} ). Patients with RSV had an adjusted hazard ratio (AHR) of 0.80 (95% CI 0.65--0.96) and patients with hMPV an AHR of 0.77 (95% CI 0.62--0.94) for symptom resolution, indicating a significantly longer symptom duration as compared with patients without RSV and hMPV, respectively. All other viral pathogens showed no significant differences in AHRs. Among patients in whom a virus was detected, there was no association between baseline viral load and duration of moderately bad or severe symptoms (AHR per unit lower Ct value 1.01, 95% CI 0.99--1.02). After stratification for viral aetiology, no significant associations were found between viral load and symptom duration.Table 3Symptom duration[a](#tbl3fna){ref-type="table-fn"} (days) in patients consulting in primary care with detected virus or no detected virus (*n* = 2393)Table 3Median (IQR) time to resolution of symptoms rated moderately bad or worseUnadjusted hazard ratio (95% CI)Adjusted hazard ratio (95% CI)[b](#tbl3fnb){ref-type="table-fn"}No virus(es) (*n* = 1288)6 (4--10)(Ref)(Ref)≥1 of six viruses (*n* = 1105)7 (5--11)0.93 (0.86--1.01)0.93 (0.86--1.02)No virus(es) (*n* = 1288)6 (4--10)(Ref)(Ref)1 of six viruses (*n* = 1056)7 (5--11)0.94 (0.87--1.03)0.94 (0.86--1.03)2 of six viruses (*n* = 49)8 (5--15)0.74 (0.55--1.00)0.76 (0.56--1.03)CoV (*n* = 177)[c](#tbl3fnc){ref-type="table-fn"}7 (4--11)0.92 (0.78--1.09)0.95 (0.80--1.12)[d](#tbl3fnd){ref-type="table-fn"}hMPV (*n* = 108)[c](#tbl3fnc){ref-type="table-fn"}8 (6--12)0.80 (0.65--0.98)0.77 (0.62--0.94)[d](#tbl3fnd){ref-type="table-fn"}Influenza (*n* = 243)[c](#tbl3fnc){ref-type="table-fn"}7 (5--10)1.12 (0.97--1.28)1.08 (0.93--1.24)[d](#tbl3fnd){ref-type="table-fn"}PiV (*n* = 60)[c](#tbl3fnc){ref-type="table-fn"}8 (5--11)0.98 (0.75--1.28)0.97 (0.74--1.26)[d](#tbl3fnd){ref-type="table-fn"}Rhinovirus (*n* = 445)[c](#tbl3fnc){ref-type="table-fn"}7 (5--11)0.90 (0.81--1.01)0.93 (0.83--1.04)[d](#tbl3fnd){ref-type="table-fn"}RSV (*n* = 121)[c](#tbl3fnc){ref-type="table-fn"}8 (5--14)0.79 (0.65--0.96)0.80 (0.65--0.96)[d](#tbl3fnd){ref-type="table-fn"}[^10][^11][^12][^13][^14]Fig. 4Cox regression survival curves for the duration of symptoms rated moderately bad or worse in patients with lower respiratory tract infections (LRTIs) and a viral mono-infection (*n* = 2344), stratified by detected virus. The reference category is no virus detected. Survival curves are derived from multivariate Cox regression models with adjustment for bacterial coinfections, age, gender, pulmonary comorbidities (asthma, chronic obstructive pulmonary disease and other lung diseases), heart failure, current smoking, influenza vaccination during the preceding fall or winter and duration of symptoms before presentation. CoV, coronavirus; hMPV, human metapneumovirus; PiV, parainfluenza virus; RSV, respiratory syncytial virus.Fig. 4

Discussion {#sec4}
==========

Adult patients visiting the GP with acute cough or suspected LRTI due to influenza virus, hMPV, RSV, CoV or rhinovirus had a 0.07--0.25 points (or 2--8%) higher mean symptom severity score (range 1--4) at presentation as compared with patients presenting with acute cough or suspected LRTI without detection of one of these respiratory viruses. In translation, patients with RSV -- who have a 0.12-point (4%) higher symptom score at presentation than patients in whom no virus is detected -- rate one or two symptoms severe instead of moderate, moderate instead of mild, or mild instead of absent. Additionally, RSV and hMPV were associated with a longer duration of moderately bad or severe symptoms, which might be linked to the pattern of immune response to these viruses \[[@bib21]\]. For all respiratory viruses together, a higher viral load measured at presentation, was significantly associated with a higher symptom severity. This was caused by significant associations between viral load and symptom severity for rhinovirus and RSV. There was no association between viral load and the duration of moderately bad or severe symptoms.

Clinical implications {#sec4.1}
---------------------

This study does not provide direct clinically actionable insight. However, although we do not provide recommendations on clinical management or treatment, we do think that the large number of patients included in this study provides important information which can be used to prioritize different respiratory viruses in the primary care setting. Currently, public health resources in the general community are guided by the aim to prevent complications in the most vulnerable people, and are focused almost exclusively on influenza \[[@bib11],[@bib22],[@bib23]\]. From a socio-economic perspective, however, targeting public health resources only at influenza virus neglects the substantial illness course in the community caused by other respiratory viruses. From our results we conclude that RSV and hMPV impose a disease burden that compares well to that of influenza virus and should therefore receive more attention in the primary care setting, e.g., by supporting the development and implementation of prevention approaches such as vaccines \[[@bib24], [@bib25], [@bib26]\].

Strengths and limitations {#sec4.2}
-------------------------

Despite the fact that we had a large cohort in which data were collected in a standardized manner, and outcome measures were in line with previous studies \[[@bib14],[@bib17], [@bib18], [@bib19]\], there are several potential sources of bias that might limit the validity of our results. Firstly, it is possible that non-agreement of patients to participate in this observational study was not random. The extent to which this selection might be present is uncertain because we have no information on the number and characteristics of patients who declined participation. Secondly, the use of medication, such as antibiotic treatment, antiviral treatment, (over-the-counter) symptomatic treatment, and prophylactic antibiotics with antiviral effects (as azithromycin) might have influenced outcomes. We consider it unlikely that receiving antibiotics caused biased results, because the in-study amoxicillin trial showed no differences in outcomes between the intervention and placebo groups \[[@bib14]\]. Because only two patients in our cohort were prescribed antivirals (oseltamivir), we consider the effect of antiviral treatment also negligible. Unavailability of data on the use of prophylactic antibiotics and symptomatic medication made adjustment for these factors impossible. Thirdly, there might be bias in the self-reporting of symptoms by patients. However, previous studies showed a high internal reliability, validity and sensitivity of the symptom diary we used \[[@bib15]\]. Also, because the 95/207 (46%) patients who did not meet the event criteria and who did not fill out their symptom diary completely were censored for the analysis, we do not expect selection bias due to loss of follow-up. Fourthly, the required sample size for the prospective observational cohort was not determined on the specific requirements of the current study. Hence, inconclusive or non-significant results can therefore not be considered definite to prove the absence of associations. We specifically chose not to correct for multiple testing, as this correction may have further hampered statistical power, especially for viruses only detected in a limited number of patients. Fifthly, the relatively low overall percentage of detected viruses might have been caused by the inclusion of patients with quite long duration of symptoms. Because respiratory fluids are renewed quickly in the patient, viral pathogens in patients with longer duration of symptoms might therefore not have been detectable anymore. Finally, a higher viral load was associated with a higher symptom severity at presentation. Looking at specific viruses we only found this association for RSV and rhinovirus, which confirms previous studies \[[@bib27], [@bib28], [@bib29]\]. However, the interpretation of single viral load measurements is difficult. Not only are viral loads of respiratory viruses highly dependent on variation in sampling location and technique, they also rise and fall rapidly and it is known that symptoms mostly follow the viral load \[[@bib30],[@bib31]\].

In conclusion, in this study among relatively healthy adult patients presenting in a primary care setting with acute cough and/or a suspected LRTI, influenza virus, hMPV, RSV, CoV and rhinovirus were associated with an increased symptom severity at presentation as compared with patients without a detected virus. In this general community population, RSV and hMPV were associated with a longer duration of moderately bad or severe symptoms. This study emphasizes that public health policies as vaccinations and awareness among GPs should not remain focused on influenza virus exclusively, but should also include other common respiratory viruses such as RSV and hMPV that pose a high socio-economic burden to the general adult community.
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Appendix A. Supplementary data {#appsec1}
==============================

The following are the Supplementary data to this article:Multimedia component 1Multimedia component 1 Multimedia component 2Multimedia component 2

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.cmi.2020.03.023>.

[^1]: COPD, chronic obstructive pulmonary disease.

[^2]: Demographics are given as absolute numbers with % for categorical variables or as median with interquartile range for continuous variables.

[^3]: Some patients had multiple comorbidities.

[^4]: Prescribed medication included antibiotics, antitussives, mucolytic drugs, antihistamines, bronchodilators and anti-inflammatory drugs.

[^5]: CI, confidence interval; CoV, coronavirus; hMPV, human metapneumovirus; Piv, parainfluenza; RSV, respiratory syncytial virus; SD, standard deviation.

[^6]: Calculated as the mean (SD) symptom severity score for all 12 symptoms at presentation.

[^7]: Estimates controlled for age, gender, pulmonary comorbidities (asthma, chronic obstructive pulmonary disease and other lung diseases), hearth failure, current smoking, influenza vaccination during the preceding fall or winter, coinfection with at least one respiratory bacterium or with Aspergillus and duration of symptoms before presentation.

[^8]: Reference group is no CoV, hMPV, influenza virus, PiV, rhinovirus or RSV, respectively.

[^9]: By including all six viruses in the model, estimates were additionally controlled for coinfection with another respiratory virus.

[^10]: A hazard ratio \<1 indicates a disadvantageous effect on symptom resolution. CI, confidence interval; CoV, coronavirus; hMPV, human metapneumovirus; IQR, interquartile range; Piv, parainfluenza; RSV, respiratory syncytial virus.

[^11]: Calculated as the median (IQR) number of days with symptoms rated moderately bad or worse by the patient following initial presentation.

[^12]: Estimates controlled for age, gender, pulmonary comorbidities (asthma, chronic obstructive pulmonary disease and other lung diseases), heart failure, current smoking, influenza vaccination during the preceding fall or winter, coinfection with at least one respiratory bacterium or with Aspergillus and duration of symptoms before presentation.

[^13]: Reference group is no CoV, hMPV, influenza virus, PiV, rhinovirus or RSV, respectively.

[^14]: By including all six viruses in the model, estimates were additionally controlled for coinfection with another respiratory virus.
